Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care has raised $150 million in equity financing. With over 160 systems installed worldwide, company’s proprietary technology has been used in nearly 20,000 commercial applications and is currently FDA approved as an incisionless, immediate treatment for patients suffering from essential tremor and Parkinson’s disease.
Read also – Bullhorn Acquires Textkernel to Accelerate Its AI strategy
The round was led by Fidelity Management & Research Company and co-led by Nexus Neurotech Ventures and Ally Bridge Group. Support from new investors, Baillie Gifford, Catalio Capital Management, Fayez Sarofim & Co., and Gilmartin Capital, along with strong support from insiders, led by affiliates of York Global Finance / Community Fund and Perceptive Advisors generated an oversubscribed round.
Read also – Fintech Platform Knot Partners With Plaid
“We are grateful for the strong support of our mission from these new and existing investors,” said Maurice R Ferré, M.D., CEO and chairman of the board of Insightec. “This financing provides Insightec with runway to expand incisionless neurosurgery to the many patients suffering from movement disorders and continue to make calculated and strategic investments in new indications.”
About Insightec
Insightec is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of focused ultrasound. The company’s Exablate Prime platform focuses sound waves, safely guided by MRI, to provide tremor treatment to patients with medication-refractory essential tremor and Parkinson’s disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. Insightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Shanghai, and Tokyo.
